Advanced Search
Current and Breaking News for Professionals, Consumers and Media



Click here to learn how to advertise on this site and for ad rates.

FDA Approval Author: FDA Consumer Health Information Last Updated: Jul 7, 2016 - 5:36:25 PM



FDA Approves First Seasonal Influenza Vaccine Manufactured Using Cell Culture Technology

By FDA Consumer Health Information
Nov 20, 2012 - 8:58:57 PM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page
(HealthNewsDigest.com) - The U.S. Food and Drug Administration announced today the approval of Flucelvax, the first seasonal influenza vaccine licensed in the United States produced using cultured animal cells, instead of fertilized chicken eggs. Flucelvax is approved to prevent seasonal influenza in people ages 18 years and older.

The manufacturing process for Flucelvax is similar to the egg-based production method, but a significant difference is that the virus strains included in the vaccine are grown in animal cells of mammalian origin instead of in eggs. Cell culture technology has already been in use for several decades to produce other U.S. licensed vaccines.

“Today’s approval represents the culmination of efforts to develop a seasonal influenza vaccine using cell culture as an alternative to the egg-based process,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research.

Cell culture technology is another manufacturing alternative to conventional egg-based influenza vaccine production. Advantages of cell culture technology include the ability to maintain an adequate supply of readily available, previously tested and characterized cells for use in vaccine production and the potential for a faster start-up of the vaccine manufacturing process in the event of a pandemic.

Flucelvax was evaluated in a randomized controlled clinical study conducted in the United States and Europe that involved about 7,700 people ages 18 to 49 years who received either Flucelvax or a placebo. The study showed that Flucelvax was 83.8 percent effective in preventing influenza when compared to placebo. The use of Flucelvax in people older than 49 is supported by antibody responses in about 1,700 adults which showed it to be comparable to Agriflu, an egg-based seasonal influenza vaccine approved by FDA for use in people 18 years and older.

The safety evaluation included about 6,700 individuals who received Flucelvax in controlled clinical studies. Injection site and general reactions to Flucelvax were typical of those seen with current influenza vaccines. Pain, redness and soreness at the injection site and headache and fatigue were the most common reactions.

Getting vaccinated each year remains one of the best ways to prevent seasonal influenza. The Centers for Disease Control and Prevention recommends that everyone 6 months of age and older receive an annual influenza vaccine.

Flucelvax is manufactured by Novartis Vaccines and Diagnostics GmbH, Marburg, Germany.

For more information:

- Flu.gov: consumer site for flu information
- FDA: Influenza Vaccine Safety & Availability
- CDC: Seasonal Influenza – Who should get vaccinated against influenza (Flu)
- Flu Vaccine Finder

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

# # #

For advertising and promotion on HealthNewsDigest.com please contact Mike McCurdy: [email protected] or 877-634-9180
HealthNewsDigest.com is syndicated worldwide, to thousands of journalists in all media, and health-related websites. www.HealthNewsDigest.com


Top of Page

HealthNewsDigest.com

FDA Approval
Latest Headlines


+ FDA Approves First Cancer Treatment for Any Solid Tumor With a Specific Genetic Feature
+ FDA Approves Drug to Treat ALS
+ FDA Approves Urea Cycle Disorder Treatment for Use in Children as Young as Two Months
+ Novartis Receives FDA Approval for Rydapt® in Newly Diagnosed FLT3-mutated Acute Yeloid Leukemia (AML)
+ FDA Approves New Combination Treatment for Acute Myeloid Leukemia
+ FDA Approves New Drug to Treat Hepatocellular Carcinoma, the Most Common Form of Liver Cancer
+ FDA Expands Approved Use of Stivarga to Treat Liver Cancer
+ FDA Approves First Treatment for Rare Form of Skin Cancer
+ Velano Vascular Receives Third FDA 510(k) Clearance for Innovative PIVO Needle-Free Blood Draw Technology
+ FDA Approves New Psoriasis Drug



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions